CVKD — Cadrenal Therapeutics, Inc. Common Stock
$0.9600-1.03%
Last close: · regular session
After-hours $0.9861 +2.72% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for CVKD in the TickerWise workspace.
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Global Market
- Employees: 4
- Website: https://www.cadrenal.com
Latest SEC filings for CVKD
Latest CVKD news
- Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.